These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 35903156)

  • 1. Safety of Intranasal Insulin in Type 2 Diabetes on Systemic Insulin: A Double-Blinded Placebo-Controlled Sub-Study of Memaid Trial.
    Aponte Becerra L; Galindo Mendez B; Khan F; Lioutas V; Novak P; Mantzoros CS; Ngo LH; Novak V
    Arch Diabetes Obes; 2022; 4(2):403-415. PubMed ID: 35903156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial.
    Novak V; Mantzoros CS; Novak P; McGlinchey R; Dai W; Lioutas V; Buss S; Fortier CB; Khan F; Aponte Becerra L; Ngo LH
    J Neurol; 2022 Sep; 269(9):4817-4835. PubMed ID: 35482079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memory advancement by intranasal insulin in type 2 diabetes (MemAID) randomized controlled clinical trial: Design, methods and rationale.
    Galindo-Mendez B; Trevino JA; McGlinchey R; Fortier C; Lioutas V; Novak P; Mantzoros CS; Ngo L; Novak V
    Contemp Clin Trials; 2020 Feb; 89():105934. PubMed ID: 31923471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily intranasal insulin at 40IU does not affect food intake and body composition: A placebo-controlled trial in older adults over a 24-week period with 24-weeks of follow-up.
    Becerra LA; Gavrieli A; Khan F; Novak P; Lioutas V; Ngo LH; Novak V; Mantzoros CS
    Clin Nutr; 2023 Jun; 42(6):825-834. PubMed ID: 37084469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study.
    Novak P; Pimentel Maldonado DA; Novak V
    PLoS One; 2019; 14(4):e0214364. PubMed ID: 31022213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk - Study rationale and design.
    Davidy T; Yore I; Cukierman-Yaffe T; Ravona-Springer R; Livny A; Lesman-Segev OH; Azuri Y; Carmichael O; Kapogiannis D; Zetterberg H; Lin H; Sano M; Beeri MS
    Mech Ageing Dev; 2023 Jul; 213():111825. PubMed ID: 37245533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness of continuous subcutaneous insulin pumps with continuous glucose monitoring in outpatient adolescents with type 1 diabetes: A systematic review.
    Matsuda E; Brennan P
    JBI Libr Syst Rev; 2012; 10(42 Suppl):1-10. PubMed ID: 27820140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).
    Riddle MC; Aronson R; Home P; Marre M; Niemoeller E; Miossec P; Ping L; Ye J; Rosenstock J
    Diabetes Care; 2013 Sep; 36(9):2489-96. PubMed ID: 23628617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal insulin suppresses endogenous glucose production in humans compared with placebo in the presence of similar venous insulin concentrations.
    Dash S; Xiao C; Morgantini C; Koulajian K; Lewis GF
    Diabetes; 2015 Mar; 64(3):766-74. PubMed ID: 25288674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design.
    Davidy T; Yore I; Cukierman-Yaffe T; Ravona-Springer R; Livny A; Lesman-Segev OH; Azuri Y; Carmichael O; Kapogiannis D; Zetterberg H; Lin H; Sano M; Beeri MS
    Mech Ageing Dev; 2024 Apr; 218():111898. PubMed ID: 38159613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
    Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
    Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Insulin Analogs on Frequency of Non-Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-Monitoring of Blood Glucose-The HypoAna Trial.
    Agesen RM; Kristensen PL; Beck-Nielsen H; Nørgaard K; Perrild H; Jensen T; Parving HH; Thorsteinsson B; Tarnow L; Pedersen-Bjergaard U
    Diabetes Technol Ther; 2018 Mar; 20(3):247-256. PubMed ID: 29565719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cognitive behavioral therapy intervention to reduce fear of hypoglycemia in young adults with type 1 diabetes (FREE): study protocol for a randomized controlled trial.
    Martyn-Nemeth P; Duffecy J; Quinn L; Park C; Mihailescu D; Penckofer S
    Trials; 2019 Dec; 20(1):796. PubMed ID: 31888691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dropout risk and effectiveness of retention strategies in the Memory Advancement by Intranasal Insulin in Type 2 Diabetes (MemAID) Clinical Trial.
    Isaza-Pierrotti DF; Khan F; Novak P; Lioutas V; Mantzoros CS; Ngo LH; Novak V
    Contemp Clin Trials; 2023 Feb; 125():107057. PubMed ID: 36539060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes.
    Rodbard D
    Diabetes Technol Ther; 2017 Jun; 19(S3):S25-S37. PubMed ID: 28585879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High incidence of hypoglycemia in stable insulin-treated type 2 diabetes mellitus: continuous glucose monitoring vs. self-monitored blood glucose. Observational prospective study.
    Pazos-Couselo M; García-López JM; González-Rodríguez M; Gude F; Mayán-Santos JM; Rodríguez-Segade S; Rodríguez-García J; Casanueva F
    Can J Diabetes; 2015 Oct; 39(5):428-33. PubMed ID: 26254702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
    Frandsen CS; Dejgaard TF; Holst JJ; Andersen HU; Thorsteinsson B; Madsbad S
    Diabetes Care; 2015 Dec; 38(12):2250-7. PubMed ID: 26486191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study).
    Danne T; Philotheou A; Goldman D; Guo X; Ping L; Cali A; Johnston P
    Pediatr Diabetes; 2013 Dec; 14(8):593-601. PubMed ID: 23730996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycemic Variability and Hypoglycemic Excursions With Continuous Glucose Monitoring Compared to Intermittently Scanned Continuous Glucose Monitoring in Adults With Highest Risk Type 1 Diabetes.
    Avari P; Moscardo V; Jugnee N; Oliver N; Reddy M
    J Diabetes Sci Technol; 2020 May; 14(3):567-574. PubMed ID: 31375042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.